Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease

Clinical Neuropharmacology

Volumn 30, Issue 1, 2007, Pages 18-24

  Stocchi, Fabrizio ^a   Fabbri, Laura ^b   Vecsei, Laszlo ^c   Krygowska Wajs, Anna ^d   Monici Preti, Piero Alessandro ^b   Ruggieri, Stefano A ^e  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CHIESI FARMACEUTICI S P A   (Italy)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e IRCCS NEUROMED   (Italy)

Author keywords

Afternoon "off" period; Carbidopa; Latency to "on"; Levodopa; Levodopa methyl ester; Melevodopa; Motor fluctuation; Parkinson disease

Indexed keywords

CARBIDOPA; CHF 1512; LEVODOPA; LEVODOPA METHYL ESTER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EFFERVESCENT TABLET; FATIGUE; FEMALE; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SYSTOLE; THORAX PAIN; TREATMENT DURATION; VOMITING;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MOTOR ACTIVITY; MOTOR SKILLS DISORDERS; NAUSEA; PARKINSON DISEASE;

EID: 33846837447     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000236762.77913.C6     Document Type: Article

References (15)

1. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-296.
2. Lang AP, Lozano AE. Parkinson's disease. N Engl J Med 1998;339:1044-1053.
3. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23(suppl 2):2-7.
4. Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 2003;9(suppl 2):73-81.
5. Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease. Arch Neurol 2005;62:905-910.
6. Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 2003;26:196-198.
7. Stocchi F, Barbato L, Bramante L, et al. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double blind cross-over study vs placebo. Funct Neurol 1994;9:259-264.
8. Steiger MJ, Stocchi F, Carta A, et al. The clinical efficacy of oral levodopa methyl ester in reversing "Off" periods in PD. Clin Neuropharmacol 1991;14:241-244.
9. Steiger MJ, Stocchi F, Bramante L, et al. The clinical efficacy of single morning doses of levodopa methyl ester dispersible Madopar and Sinemet Plus in Parkinson's disease. Clin Neuropharmacol 1992;15:501-504.
10. Stocchi F, Barbato L, Bramante L, et al. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J Neurol 1996;243:377-380.
11. Ruggieri S, Stocchi F, Carta A, et al. Comparison between oral L-dopa and oral L-dopa methyl ester in fluctuating Parkinson's disease. In: Bartko D, et al., ed. New Trends Clinical Neuropharmacol. London: John Libbey Ltd; 1988:268-272.
12. Stocchi F, Ruggieri S, Carta A, et al. Different therapeutic approaches to complicated Parkinson disease. In: Quinn NP, Jenner PG, eds. Disorders of Movement. London: Academy Press; 1989:137-146.
13. Rondelli , Acerbi D, Mariotti F, et al. Simultaneous determination of L-dopa methylester, L-dopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. Chromatog: Biomed Appl 1994;653:17-21.
14. Vickers S, Duncan CA, White SD, et al. Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog and rat. Drug Metab Dispos 1978;6:640.
15. Sasahara K, Nitanai T, Habara T, et al. Dosage form design for improvement of bioavailability of L-dopa III: influence of dose on pharmacokinetic behavior of L-dopa in dogs and parkinsonian patients. J Pharm Sci 1980;69:1374-1378.